Report cover image

North America Cancer Immunotherapy Market, By Type of Therapy (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, Oncolytic Virus); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By A

Publisher BlueWeave Consulting
Published Apr 24, 2024
Length 200 Pages
SKU # BLWC18805939

Description

North America Cancer Immunotherapy Market, By Type of Therapy (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, Oncolytic Virus); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Others (Ovarian Cancer, Pancreatic Cancer)); By End User (Hospitals & Clinics, Cancer Research Centers); By Country (United States, Canada), Trend Analysis, Competitive Landscape & Forecast, 2019–2030


North America Cancer Immunotherapy Market Size More Than Doubles at Robust CAGR of 11.15% to Surpass USD 68.5 Billion by 2030

North America Cancer Immunotherapy Market is expanding rapidly due to expanding approval of immunotherapeutic drugs for the treatment of increasing incidences of cancer and increasing investments in immunotherapy research and development programs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the North America Cancer Immunotherapy Market size by value at USD 24.61 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the North America Cancer Immunotherapy Market size to expand at a CAGR of 11.15% reaching a value of USD 68.52 billion by 2030. The North America Cancer Immunotherapy Market is primarily driven by the increasing incidence of cancer cases, rising demand for personalized medicine, advancements in biotechnology, and a growing understanding of immune checkpoints. Additionally, favorable government initiatives, extensive R&D activities, and collaborations among pharmaceutical companies contribute to market growth. Moreover, the introduction of novel immunotherapeutic agents, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, alongside expanding applications across various cancer types, further propel the market forward. The rapid adoption of immunotherapy as a standard treatment option, coupled with improving healthcare infrastructure, also fosters market expansion in North America.

Opportunity – Growing focus on personalized medicine

The rising emphasis on personalized medicine is fueling significant growth of the North America Cancer Immunotherapy Market. With advancements in genomic profiling and targeted therapies, personalized treatment approaches are becoming increasingly prevalent. The shift towards individualized care enables better outcomes and reduced side effects for patients, spurring adoption rates and market expansion. As the demand for precision medicine continues to rise, the market is poised for sustained growth, revolutionizing cancer treatment strategies across the region.

Impact of Escalating Geopolitical Tensions on North America Cancer Immunotherapy Market

Escalating geopolitical tensions can significantly impact the North America Cancer Immunotherapy Market. Restrictions on trade, sanctions, or disruptions in supply chains due to geopolitical conflicts can hinder the availability of crucial immunotherapy drugs and technologies. Increased uncertainty may lead to fluctuations in investments and research funding, affecting the development of innovative therapies. Additionally, diplomatic tensions may impede international collaboration and hinder the exchange of scientific knowledge, potentially slowing down advancements in cancer immunotherapy. Further, geopolitical instability can affect healthcare infrastructure and access to treatment, particularly for vulnerable populations, thereby impacting the market's growth and adoption of immunotherapies. Overall, the North America Cancer Immunotherapy Market could face challenges in terms of research, development, accessibility, and investment amidst escalating geopolitical tensions.

North America Cancer Immunotherapy Market

Segmental Coverage

North America Cancer Immunotherapy Market – By Type of Therapy

Based on type of therapy, North America Cancer Immunotherapy Market is divided into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus segments. The checkpoint inhibitors segment is the largest type of therapy in the North America Cancer Immunotherapy Market. These inhibitors, which include drugs like pembrolizumab and nivolumab, have garnered significant attention for their ability to enhance the body's immune response against cancer cells by blocking certain checkpoints that inhibit immune system activity. With extensive research and development efforts and proven efficacy in various cancer types, checkpoint inhibitors stand out as the leading segment, driving substantial market growth and adoption among healthcare providers and patients across North America.

North America Cancer Immunotherapy Market – By Distribution Channel

Based on distribution channel, North America Cancer Immunotherapy Market is divided into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy segments. The hospital pharmacy segment typically represents the largest distribution channel, owing to its accessibility, specialized oncology care, and availability of advanced immunotherapeutic treatments. Hospitals often serve as primary centers for cancer diagnosis, treatment, and management, thus witnessing higher demand for immunotherapy drugs. The segment's prominence underscores the crucial role hospitals play in cancer care delivery in the region, emphasizing the importance of healthcare infrastructure in facilitating effective cancer immunotherapy treatments.

Competitive Landscape

North America Cancer Immunotherapy Market is fiercely competitive. Major companies in the market include Pfizer Inc., AstraZeneca, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc., Bayer AG, Astellas Pharma Inc., Gilead Sciences, Inc., GSK plc, Sanofi, AbbVie Inc., and Atara Biotherapeutics, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in the North America Cancer Immunotherapy Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of North America Cancer Immunotherapy Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in North America Cancer Immunotherapy Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

200 Pages
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. North America Cancer Immunotherapy Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising cancer incidence
3.2.1.2. Growing awareness and acceptance of immunotherapy
3.2.1.3. Increasing government initiatives
3.2.2. Restraints
3.2.2.1. High cost of treatment
3.2.2.2. Increasing safety concerns
3.2.2.3. Complex regulatory landscape
3.2.3. Opportunities
3.2.3.1. Development of new and improved immunotherapy drugs
3.2.3.2. Growing focus on personalized medicine
3.2.3.3. Expansion into new indications
3.2.4. Challenges
3.2.4.1. Educating patients and healthcare providers
3.2.4.2. Manufacturing challenges
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. North America Cancer Immunotherapy Market: Marketing Strategies
5. North America Cancer Immunotherapy Market Overview
5.1. Market Size & Forecast, 2019–2030
5.1.1. By Value (USD Billion)
5.2. Market Share and Forecast
5.2.1. By Type of Therapy
5.2.1.1. Checkpoint Inhibitors
5.2.1.2. Monoclonal Antibodies
5.2.1.3. Vaccines
5.2.1.4. Cell Therapies
5.2.1.5. Immunomodulators
5.2.1.6. Oncolytic Virus
5.2.2. By Distribution Channel
5.2.2.1. Hospital Pharmacy
5.2.2.2. Retail Pharmacy
5.2.2.3. Online Pharmacy
5.2.3. By Application
5.2.3.1. Lung Cancer
5.2.3.2. Breast Cancer
5.2.3.3. Colorectal Cancer
5.2.3.4. Melanoma
5.2.3.5. Prostate Cancer
5.2.3.6. Others (Ovarian Cancer, Pancreatic Cancer)
5.2.4. By End User
5.2.4.1. Hospitals & Clinics
5.2.4.2. Cancer Research Centers
5.2.4.3. Others
5.2.5. By Country
5.2.5.1. United States
5.2.5.2. Canada
6. United States Cancer Immunotherapy Market
6.1. Market Size & Forecast, 2019–2030
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Type of Therapy
6.2.2. By Distribution Channel
6.2.3. By Application
6.2.4. By End User
7. Canada Cancer Immunotherapy Market
7.1. Market Size & Forecast, 2019–2030
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Distribution Channel
7.2.3. By Application
7.2.4. By End User
8. Competitive Landscape
8.1. List of Key Players and Their Offerings
8.2. North America Cancer Immunotherapy Market Share Analysis, 2023
8.3. Competitive Benchmarking, By Operating Parameters
8.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
9. North America Cancer Immunotherapy Market: Import & Export
10. Impact of Geopolitical Tensions on North America Cancer Immunotherapy Market
11. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
11.1. Pfizer Inc.
11.2. AstraZeneca
11.3. Merck & Co., Inc
11.4. F. Hoffmann-La Roche Ltd
11.5. Bristol-Myers Squibb Company
11.6. Novartis AG
11.7. Lilly
11.8. Johnson & Johnson Services, Inc
11.9. Bayer AG
11.10. Astellas Pharma Inc.
11.11. Gilead Sciences, Inc
11.12. GSK plc
11.13. Sanofi
11.14. AbbVie Inc.
11.15. Atara Biotherapeutics, Inc
11.16. Other Prominent Players
12. Key Strategic Recommendations
13. Research Methodology
13.1. Qualitative Research
13.1.1. Primary & Secondary Research
13.2. Quantitative Research
13.3. Market Breakdown & Data Triangulation
13.3.1. Secondary Research
13.3.2. Primary Research
13.4. Breakdown of Primary Research Respondents, By Region
13.5. Assumptions & Limitations
*Financial information of case of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
Figure 1 North America Cancer Immunotherapy Segmentation
Figure 2 North America Cancer Immunotherapy Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2023
Figure 4 North America Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Figure 5 North America Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Figure 6 North America Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Figure 7 North America Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Figure 8 North America Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
Figure 9 North America Cancer Immunotherapy Market Share, By Country, By Value (USD Billion), 2019–2030
Figure 10 United States Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Figure 11 United States Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Figure 12 United States Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Figure 13 United States Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Figure 14 United States Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
Figure 15 Canada Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Figure 16 Canada Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Figure 17 Canada Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Figure 18 Canada Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Figure 19 Canada Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
List of Tables
Table 1 North America Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Table 2 North America Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Table 3 North America Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Table 4 North America Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Table 5 North America Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
Table 6 North America Cancer Immunotherapy Market Share, By Country, By Value (USD Billion), 2019–2030
Table 7 United States Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Table 8 United States Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Table 9 United States Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Table 10 United States Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Table 11 United States Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
Table 12 Canada Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030
Table 13 Canada Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030
Table 14 Canada Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030
Table 15 Canada Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030
Table 16 Canada Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030
Table 17 Pfizer Inc. Company Overview
Table 18 Pfizer Inc. Financial Overview
Table 19 AstraZeneca Company Overview
Table 20 AstraZeneca Financial Overview
Table 21 Merck & Co., Inc Company Overview
Table 22 Merck & Co., Inc Financial Overview
Table 23 F. Hoffmann-La Roche Ltd Company Overview
Table 24 F. Hoffmann-La Roche Ltd Financial Overview
Table 25 Bristol-Myers Squibb Company: Company Overview
Table 26 Bristol-Myers Squibb Company Financial Overview
Table 27 Novartis AG Company Overview
Table 28 Novartis AG Financial Overview
Table 29 Lilly Company Overview
Table 30 Lilly Financial Overview
Table 31 Johnson & Johnson Services, Inc Company Overview
Table 32 Johnson & Johnson Services, Inc Financial Overview
Table 33 Bayer AG Company Overview
Table 34 Bayer AG Financial Overview
Table 35 Astellas Pharma Inc. Company Overview
Table 36 Astellas Pharma Inc. Financial Overview
Table 37 Gilead Sciences, Inc Company Overview
Table 38 Gilead Sciences, Inc Financial Overview
Table 39 GSK plc Company Overview
Table 40 GSK plc Financial Overview
Table 41 Sanofi Company Overview
Table 42 Sanofi Financial Overview
Table 43 AbbVie Inc. Company Overview
Table 44 AbbVie Inc. Financial Overview
Table 45 Atara Biotherapeutics, Inc Company Overview
Table 46 Atara Biotherapeutics, Inc Financial Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us